- T2 Biosystems (NASDAQ:TTOO) on Tuesday reported preliminary record product revenue of $2.3 million for the fourth quarter of 2024 and $8.3 million for the full year of 2024, representing increases of 37% and 23%, respectively, over the prior-year period. driven by record sales of sepsis tests.
- Cash and cash equivalents were $1.7 million at December 31, 2024.
- It's TTOO +2.17% to $0.4189.
- Source: Press release